Small increases in eosinophil counts were observed at week 4 in lebrikizumab patients; these changes were transient, and levels approached baseline values by week 16 (eFigure 4 in Supplement 2). Discussion During 16 weeks of treatment, lebrikizumab showed rapid, dose-dependent efficacy across a ...
18 To evaluate the importance of predictors obtained from invasive tests, a sensitivity analysis was performed, adding skin prick test (at 3 years of age) and blood eosinophil test (at 1 year of age) data into CHART. Study Outcomes Within the CHILD cohort, 3-year diagnoses using CHART, ...